Log in

Healthcare

Trial data, approvals, and what they are worth

Readouts, FDA decisions, drug pricing and payer behaviour, sized in revenue rather than in press-release adjectives.

What Big Funds Own42 fundsWhat Berkshire, Bridgewater and other big funds reported holding last quarter.What Analysts Expect16 stocksRatings and price targets from the big institutions, each with its public source.

2026-07-13

Medicare Advantage recovery graphic with shield, claims flow, and margin repair signals
Healthcare / Earnings
UNH · ELV•10 min read

UnitedHealth and Elevance Health Are the Next Test of the Medicare Advantage Recovery

The next two insurer calls will tell the market whether the 2026 MA payment reset and easing utilization are enough to extend the rally in UnitedHealth, Elevance Health, and peers, or whether medical-cost inflation is starting to creep back.

MA payment update: +5.06%Elevance call: Jul 15
Read article

2026-07-11

Healthcare AI assistant, longitudinal care, and patient management graphic
AI / Healthcare
GOOGL•9 min read

Google's AMIE Turns Healthcare AI Into Disease-Management Infrastructure

Google says AMIE can reason through longitudinal disease management as well as, and in some respects better than, clinicians in a new Nature study. The market implication is that healthcare AI is moving beyond one-off diagnosis into workflow infrastructure for follow-up, triage, and plan quality, which matters for Alphabet, virtual-care vendors, and payer care-management stacks.

Clinicians compared: 21Study venue: Nature
Read article

2026-07-10

Drug supply chain registry, manufacturing nodes, and FDA visibility graphic
Healthcare / Manufacturing
LLY•10 min read

FDA's Drug-Manufacturing Registry Rule Tightens the Supply-Chain Map

The FDA proposed a rule that would let distributed manufacturers register as a single establishment, require advance notice before unit relocation, and close visibility gaps for foreign establishments that make active pharmaceutical ingredients and other drugs for U.S.-linked supply chains. The market implication is that supply-chain transparency is becoming a policy requirement, which favors manufacturers that can prove traceability and domestic resilience, including Eli Lilly and other scaled pharma operators.

Rule type: ProposedRegistration model: Single establishment
Read article

2026-07-09

Biotech trial and molecule graphic showing late-stage readout risk
Healthcare / Pharma
7 min read

AstraZeneca's Wainua Trial Miss Shows Late-Stage Biotech Risk Still Reprices Fast

AstraZeneca's Phase III CARDIO-TTRansform readout failed its primary objective, and the market immediately repriced the downside. The message is blunt: even quality pharma names can lose billions when one late-stage trial misses.

Primary endpoint: MissedAstraZeneca move: -8%
Read article

2026-07-01

Pediatric gene therapy, CRISPR editing, and biotech approval graphic
Healthcare / Biotech
VRTX · CRSP•9 min read

FDA's Casgevy Expansion Pushes Gene Therapy Down the Age Curve

The FDA expanded Casgevy to patients aged 2 years and older with sickle cell disease or transfusion-dependent beta thalassemia, making it the first gene therapy approved for children that young with SCD. The approval also arrived 53 days after filing, which signals that expedited review can materially compress the risk discount for Vertex and CRISPR Therapeutics.

New age floor: 2 yearsReview speed: 53 days
Read article

2026-06-27

Healthcare market graphic with rising capital flow, shield, and pipeline symbols
Healthcare
ABBV · LLY•8 min read

Healthcare Haven

Healthcare is getting bid as investors rotate out of overheated tech and into cash-rich, pipeline-rich names. AbbVie, Eli Lilly, and Johnson & Johnson all closed at all-time highs, and the market is rewarding balance-sheet discipline, label expansion, and smarter capital allocation instead of pure momentum.

AbbVie week: +14%Lilly week: ATH
Read article

2026-06-08

AI compute, sovereign infrastructure, and university research graphic
Semiconductors / AI
10 min read

AMD's £2 Billion UK AI Push Turns Compute Into Industrial Policy

AMD says it will invest up to £2 billion over five years in the United Kingdom, pairing sovereign AI infrastructure with university partnerships and photonic networking research. The market implication is bigger than one country: compute is becoming a geopolitical asset, and the companies that can sell the full stack get more leverage than the ones selling chips alone.

Investment: £2bnResearch partners: 2+
Read article

What to expect

Evidence-first notes with a visible point of view.

This section collects sharp takes on earnings, shareholder meetings, and market structure. Each new piece should make the thesis, the facts, and the implications obvious within the first few screens.

Expect direct analysis, not generic commentary.

Expect the data to be explicit and the argument to be easy to follow.